X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PANACEA BIOTECH VENUS REMEDIES/
PANACEA BIOTECH
 
P/E (TTM) x -4.4 -21.1 - View Chart
P/BV x 0.2 2.5 6.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PANACEA BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
PANACEA BIOTECH
Mar-14
VENUS REMEDIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs126149 84.7%   
Low Rs6182 74.2%   
Sales per share (Unadj.) Rs301.884.1 358.7%  
Earnings per share (Unadj.) Rs-24.9-18.3 135.9%  
Cash flow per share (Unadj.) Rs2.5-6.7 -38.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.383.7 350.4%  
Shares outstanding (eoy) m12.3461.25 20.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.4 22.6%   
Avg P/E ratio x-3.8-6.3 59.6%  
P/CF ratio (eoy) x36.7-17.2 -213.1%  
Price / Book Value ratio x0.31.4 23.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1547,074 16.3%   
No. of employees `0000.92.8 33.6%   
Total wages/salary Rs m3931,449 27.1%   
Avg. sales/employee Rs Th4,026.11,874.1 214.8%   
Avg. wages/employee Rs Th425.0527.0 80.6%   
Avg. net profit/employee Rs Th-331.8-407.7 81.4%   
INCOME DATA
Net Sales Rs m3,7245,154 72.3%  
Other income Rs m23100 22.5%   
Total revenues Rs m3,7475,254 71.3%   
Gross profit Rs m395-766 -51.5%  
Depreciation Rs m338711 47.6%   
Interest Rs m3541,503 23.6%   
Profit before tax Rs m-275-2,881 9.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m3217 188.1%   
Profit after tax Rs m-307-1,121 27.4%  
Gross profit margin %10.6-14.9 -71.3%  
Effective tax rate %-11.5-0.6 1,968.1%   
Net profit margin %-8.2-21.8 37.9%  
BALANCE SHEET DATA
Current assets Rs m2,6383,810 69.2%   
Current liabilities Rs m2,3058,365 27.6%   
Net working cap to sales %8.9-88.4 -10.1%  
Current ratio x1.10.5 251.3%  
Inventory Days Days135156 87.0%  
Debtors Days Days4667 68.9%  
Net fixed assets Rs m4,87114,480 33.6%   
Share capital Rs m12361 201.3%   
"Free" reserves Rs m3,496903 387.1%   
Net worth Rs m3,6195,127 70.6%   
Long term debt Rs m1,3745,832 23.6%   
Total assets Rs m7,50919,433 38.6%  
Interest coverage x0.2-0.9 -24.3%   
Debt to equity ratio x0.41.1 33.4%  
Sales to assets ratio x0.50.3 187.0%   
Return on assets %0.62.0 32.1%  
Return on equity %-8.5-21.9 38.8%  
Return on capital %1.63.6 43.5%  
Exports to sales %024.5 0.0%   
Imports to sales %13.910.2 136.2%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs m517525 98.4%   
Fx inflow Rs m01,539 0.0%   
Fx outflow Rs m517942 54.8%   
Net fx Rs m-517597 -86.5%   
CASH FLOW
From Operations Rs m514599 85.8%  
From Investments Rs m-123-438 28.1%  
From Financial Activity Rs m-387-303 127.9%  
Net Cashflow Rs m4-141 -3.0%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 30.0%  
FIIs % 0.6 1.3 44.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.6 281.4%  
Shareholders   20,121 10,259 196.1%  
Pledged promoter(s) holding % 36.4 35.1 103.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  MERCK LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - PFIZER COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS